1-4 of 4
Eli Gabayan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy of Elranatamab (ELRA) in Combination with Carfilzomib (CFZ) and Dexamethasone (DEX) in the Phase 1b MagnetisMM-20 Trial in Relapsed or Refractory Multiple Myeloma (RRMM)

Michael H. Tomasson, Eli Gabayan, Syed Abbas Ali, Gabriel Afram, Sona Ghorashi, Trish Creel, Luisa Paccagnella, Carolyn Lou, Ola Landgren
Journal: Blood
Blood (2024) 144 (Supplement 1): 1024.
https://doi.org/10.1182/blood-2024-210520
Published: 2024
Journal Articles

Magnetismm-3: An Open-Label, Multicenter, Non-Randomized Phase 2 Study of Elranatamab (PF-06863135) in Patients with Relapsed or Refractory Multiple Myeloma

Alexander Lesokhin, Shinsuke Iida, Don Stevens, Afshin Eli Gabayan, Wei Dong Ma, Sharon Sullivan, Marc-Steffen Raab
Journal: Blood
Blood (2021) 138 (Supplement 1): 1674.
https://doi.org/10.1182/blood-2021-152984
Published: 2021
Journal Articles

Long-Term Follow-Up of Patients Treated with Bortezomib Alone and in Combination with Dexamethasone as Frontline Therapy for Multiple Myeloma.

Sundar Jagannath, MD, Brian G.M. Durie, MD, Jeffrey Lee Wolf, MD, Elber S. Camacho, David Irwin, MD, Jose Lutzky, MD, Marti McKinley, BSN, Afshin Eli Gabayan, MD, Amitabha Mazumder, MD, John Crowley, PhD, Robert Vescio, MD
Journal: Blood
Blood (2006) 108 (11): 796.
https://doi.org/10.1182/blood.V108.11.796.796
Published: 2006
Journal Articles

A Phase 2 Study of Bortezomib as First-Line Therapy in Patients with Multiple Myeloma.

Sundar Jagannath, MD, Durie Brian, MD, Jeffrey L. Wolf, MD, Elber Camacho, MD, David Irwin, MD, Jose Lutzky, MD, Marti McKinley, MD, Eli Gabayan, MD, Amitabha Mazumder, MD, John Crowley, PhD, David Schenkein, MD
Journal: Blood
Blood (2004) 104 (11): 333.
https://doi.org/10.1182/blood.V104.11.333.333
Published: 2004